SD0006: A potent, selective and orally available inhibitor of p38 kinase

Pharmacology

Volumn 84, Issue 1, 2009, Pages 42-60

  Burnette, Barry L ^a   Selness, Shaun ^a   Devraj, Raj ^a   Jungbluth, Gail ^a   Kurumbail, Ravi ^a   Stillwell, Loreen ^a   Anderson, Gary ^a   Mnich, Stephen ^a   Hirsch, Jeffrey ^a   Compton, Robert ^a   De Ciechi, Pamela ^a   Hope, Heidi ^a   Hepperle, Michael ^a   Keith, Robert H ^a   Naing, Win ^a   Shieh, Huey ^a   Portanova, Joseph ^a   Zhang, Yan ^a   Zhang, Jian ^a   Leimgruber, Richard M ^a   Monahan, Joseph ^a   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Arthritis; Diarylpyrazole; Inflammation; p38 kinase; Rheumatoid arthritis; SD0006

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; COLLAGEN; CYTOKINE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SD 0006; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE DENSITY; CELL WALL; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME BINDING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOGRAPHY; RAT; SPECIES; STREPTOCOCCUS; TRANSCRIPTION INITIATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BONE DENSITY; CELL LINE; ENDOTOXEMIA; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED DBA; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PAIN; PYRAZOLES; PYRIMIDINES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649992182     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000227286     Document Type: Article

References (58)

1. Eigler A, Sinha B, Hartmann G, Endres S: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18: 487-492. (Pubitemid 27441592)
2. Barnes PJ: COPD: is there light at the end of the tunnel? Curr Opin Pharmacol 2004; 4: 263-272.
3. Shoelson SE, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-2180.
4. Taylor PC, Williams RO, Maini RN: Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 2001; 13: 611-616.
5. Tobinick EL: Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 2003; 25: 2279-2288.
6. Sandborn WJ, Faubion WA: Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 1366-1373.
7. Vincek V, Jacob SE, Nassiri M, Herbert LM, Nadji M, Kerdel FA: Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response. Int J Dermatol 2004; 43: 303-308. (Pubitemid 38559552)
8. Haraoui B: The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol 2005; 32: 46-47.
9. Rott S, Mrowietz U: Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 2005; 330: 716-720.
10. Suryaprasad AG, Prindiville T: The biology of TNF blockade. Autoimmun Rev 2003; 2: 346-357.
11. Nurmohamed MT, Dijkmans BA: Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005; 65: 661-694. (Pubitemid 40477785)
12. Kroesen S, Widmer AF, Tyndall A, Hasler P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 2003; 42: 617-621. (Pubitemid 37220869)
13. Mohan AK, Cote TR, Siegel JN, Miles BM: Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol 2003; 15: 179-184. (Pubitemid 36532595)
14. Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-1751. (Pubitemid 38725085)
15. Ehlers S: Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol 2005; 32: 35-39.
16. Hale KK, Trollinger D, Rihanek M, Manthey CL: Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages. J Immunol 1999; 162: 4246-4252. (Pubitemid 29314814)
17. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-746.
18. Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, Limburg PC: Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogenactivated protein kinase (MAPK) inhibitor. Arthritis Res Ther 2004; 6:R384-R392.
19. Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Tervaert JW, Van Der Werf TS, Ligtenberg JJ, Tulleken JE: Suppression of the clinical and cytokine response to endotoxin by RWJ- 67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001; 124: 16-20. (Pubitemid 32476930)
20. Dean JL, Sully G, Clark AR, Saklatvala J: The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004; 16: 1113-1121. (Pubitemid 38900514)
21. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M: Mitogenactivated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 2006; 26: 2399-2407. (Pubitemid 43346938)
22. Manthey CL, Wang SW, Kinney SD, Yao Z: SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J Leukoc Biol 1998; 64: 409-417.
23. Miyazawa K, Mori A, Miyata H, Akahane M, Ajisawa Y, Okudaira H: Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J Biol Chem 1998; 273: 24832-24838. (Pubitemid 28454988)
24. Dean JL, Brook M, Clark AR, Saklatvala J: p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999; 274: 264-269. (Pubitemid 29035058)
25. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DWP, Griswold DE: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000; 279:L895-L902.
26. Clark AR, Dean JL, Saklatvala J: Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003; 546: 37-44. (Pubitemid 36782279)
27. Huang H, Rose JL, Hoyt DG: p38 mitogenactivated protein kinase mediates synergistic induction of inducible nitric-oxide synthase by lipopolysaccharide and interferon-γ through signal transducer and activator of transcription 1 ser727 phosphorylation in murine aortic endothelial cells. Mol Pharmacol 2004; 66: 302-311. (Pubitemid 38989487)
28. Westra J, Limburg P, deBoer P, vanRijswijk M: Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 2004; 63: 1453-1459. (Pubitemid 39433951)
29. Takami M, Cho ES, Lee SY, Kamijo R, Yim M: Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 2005; 579: 832-838.
30. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G: Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000; 60: 1185-1195.
31. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC: Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogenactivated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 175-183. (Pubitemid 30368227)
32. McLay IM, Halley F, Souness JE, McKenna J, Benning V, Birrell M, Burton B, Belvisi M, Collis A, Constan A: The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem 2001; 9: 537-554. (Pubitemid 32244051)
33. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, van Deventer SJH, Peppelenbosch MP, van der Poll T: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 4070-4077. (Pubitemid 34298414)
34. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C, Pav S, Proto A, Swinamer A, Tong L, Torcellini C: Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 2002; 45: 2994-3008. (Pubitemid 34721521)
35. Revesz L, Blum E, Di Padova FE, Buhl T, Fei fel R, Gram H, Hiestand P, Manning U, Rucklin G: Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg Med Chem Lett 2004; 14: 3595-3599.
36. Stelmach JE, Liu L, Patel SB, Pivnichny JV, Scapin G, Singh S, Hop CECA, Wang Z, Strauss JR, Cameron PM: Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2003; 13: 277-280. (Pubitemid 35441351)
37. Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-726. (Pubitemid 37361787)
38. Saklatvala J: The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004; 4: 372-377. (Pubitemid 38987064)
39. Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, Pitzenberger SM, Selnick HG, Smith GR, Tebben A, Vacca JP, Varga SL, Agarwal L, Dancheck K, Forsyth AJ, Fletcher DS, Frantz B, Hanlon WA, Harper CF, Hofsess SJ, Kostura M, Lin J, Luell S, O'Neill EA, O'Keefe SJ, et al: Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J Med Chem 1999; 42: 2180-2190. (Pubitemid 29284237)
40. Jackson PF, Bullington JL: Pyridinylimidazole based p38 MAP kinase inhibitors. Curr Top Med Chem 2002; 2: 1011-1020.
41. de Laszlo SE, Visco D, Agarwal L, Chang L, Chin J, Croft G, Forsyth A, Fletcher D, Frantz B, Hacker C: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett 1998; 8: 2689-2694. (Pubitemid 28496653)
42. Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Schafer PH, Siekierka JJ: Potent inhibitors of the MAP kinase p38. Bioorg Med Chem Lett 1998; 8: 3335-3340. (Pubitemid 28547068)
43. Haddad JJ: VX-745. Vertex Pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 1070-1076.
44. Otwinowski Z, Minor M: Processing of Xray diffraction data collected in oscillation mode. Methods Enzymol 1997; 276A:307-326. (Pubitemid 27085611)
45. Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ: Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 1994; 367: 704-711. (Pubitemid 24984615)
46. Jones TA, Zou JY, Cowan SW, Kjeldgaard M: Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 1991; 47(pt 2):110-119.
47. Brunger AT: X-PLOR (Version 3.1): A System for X-Ray Crystallography and NMR. New Haven, Yale University Press, 1993.
48. Hemmer W, McGlone M, Tsigelny I, Taylor SS: Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase. J Biol Chem 1997; 272: 16946-16954. (Pubitemid 27289797)
49. Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H, Tocci MJ, O'Keefe SJ, O'Neill EA: The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998; 37: 13846-13853. (Pubitemid 28455562)
50. Cheung PCF, Campbell DG, Nebreda AR, Cohen P: Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J 2003; 22: 5793-5805. (Pubitemid 37408818)
51. Henklova P, Vrzal R, Papouskova B, Bednar P, Jancova P, Anzenbacherova E, Ulrichova J, Maurel P, Pavek P, Dvorak Z: SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol 2008; 593: 16-23.
52. Telliez A, Furman C, Pommery N, Henichart JP: Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 2006; 6: 187-208. (Pubitemid 43796638)
53. Williams R: Collagen-induced arthritis in mice. Methods Mol Med 2007; 136: 191-199.
54. Schwab J, Anderle S, Brown R, Dalldorf F, Thompson R: Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 1991; 59: 4436-4442.
55. Jacques C, Gosset M, Berenbaum F, Gabay C, Gerald L: The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006; 74: 371-403.
56. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross P, Teitelbaum SL: TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488. (Pubitemid 32038586)
57. Mbalaviele G, Anderson G, Jones A, De Ciechi P, Settle S, Mnich S, Thiede M, Abu-Amer Y, Portanova J, Monahan J: Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006; 317: 1044-1053. (Pubitemid 43764107)
58. Haugen E, Scharin Täng M, Isic A, Andersson B, Fu M: TNFα antagonist upregulates interleukin-6 in rats with hypertensive heart failure. Int J Cardiol 2008; 130: 64-68.